Identification of phytochemicals as potential inhibitors of Candida albicans SAP3: An in-silico approach

Zain Alhindi

Abstract


Background: Candida albicans is a major threat to human health, causing a variety of diseases. Candida albicans can overgrow and trigger infections like thrush, diaper rash, and vaginal yeast infections. Therefore, finding potential inhibitors of C. albicans from plant sources has become important, recently.

Methods: This study investigated the interaction of natural compounds (N = 450) from the ZINC database with the C. albicans SAP3 protein. PyRx tools were used to conduct molecular docking analyses, which included ligand and target receptor preparation, data analysis, and visualization.

Result: The binding energies between the natural compounds and SAP3 ranged from -8.8 to -7.8 kcal/mol, indicating that the interactions were predominantly strong. Among the compounds screened, ZINC000252509014, ZINC000252509722, ZINC000253389136, ZINC000251981944, and ZINC000252480871 were extensively explored in this study because they were found to be the best among others. Furthermore, these compounds showed favorable drug-like properties.

Conclusion: These findings lay the groundwork for future research aimed at developing potent SAP3 inhibitors to treat C. albicans infections.

Keywords: Candida albicans; SAP3 protein; Natural compounds; Virtual screening; Drug-likeness 


Full Text:

PDF

References


Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Science Translational Medicine, (2012); 4(165): 165rv113.

Benedict K, Jackson BR, Chiller T, Beer KD. Estimation of Direct Healthcare Costs of Fungal Diseases in the United States. Clinical Infectious Diseases, (2019); 68(11): 1791-1797.

Mukherjee PK, Sendid B, Hoarau G, Colombel JF, Poulain D, Ghannoum MA. Mycobiota in gastrointestinal diseases. Nature Reviews Gastroenterology & Hepatology, (2015); 12(2): 77-87.

Polvi EJ, Li X, O'Meara TR, Leach MD, Cowen LE. Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies. Cellular and Molecular Life Sciences, (2015); 72(12): 2261-2287.

Li J, Chen D, Yu B, He J, Zheng P, et al. Fungi in Gastrointestinal Tracts of Human and Mice: from Community to Functions. Microbial Ecology, (2018); 75(4): 821-829.

Gunsalus KT, Tornberg-Belanger SN, Matthan NR, Lichtenstein AH, Kumamoto CA. Manipulation of Host Diet To Reduce Gastrointestinal Colonization by the Opportunistic Pathogen Candida albicans. mSphere, (2016); 1(1): e00020-15.

Noble SM, Gianetti BA, Witchley JN. Candida albicans cell-type switching and functional plasticity in the mammalian host. Nature Reviews Microbiology, (2017); 15(2): 96-108.

Limon JJ, Skalski JH, Underhill DM. Commensal Fungi in Health and Disease. Cell Host & Microbe, (2017); 22(2): 156-165.

Alves R, Barata-Antunes C, Casal M, Brown AJP, Van Dijck P, Paiva S. Adapting to survive: How Candida overcomes host-imposed constraints during human colonization. PLOS Pathogens, (2020); 16(5): e1008478.

Ene IV, Brunke S, Brown AJ, Hube B. Metabolism in fungal pathogenesis. Cold Spring Harbor Perspectives in Medicine, (2014); 4(12): a019695.

Polke M, Hube B, Jacobsen ID. Candida survival strategies. Advances in Applied Microbiology, (2015); 91: 139-235.

Zhai B, Ola M, Rolling T, Tosini NL, Joshowitz S, et al. High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis. Nature Medicine, (2020); 26(1): 59-64.

Yan L, Yang C, Tang J. Disruption of the intestinal mucosal barrier in Candida albicans infections. Microbiological Research, (2013); 168(7): 389-395.

Alenazy H, Alghamdi A, Pinto R, Daneman N. Candida colonization as a predictor of invasive candidiasis in non-neutropenic ICU patients with sepsis: A systematic review and meta-analysis. International Journal of Infectious Diseases, (2021); 102: 357-362.

Magill SS, O'Leary E, Janelle SJ, Thompson DL, Dumyati G, et al. Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals. The New England Journal of Medicine, (2018); 379(18): 1732-1744.

Kumamoto CA, Gresnigt MS, Hube B. The gut, the bad and the harmless: Candida albicans as a commensal and opportunistic pathogen in the intestine. Current Opinion in Microbiology, (2020); 56: 7-15.

Prieto D, Correia I, Pla J, Roman E. Adaptation of Candida albicans to commensalism in the gut. Future Microbiology, (2016); 11(4): 567-583.

Borelli C, Ruge E, Schaller M, Monod M, Korting HC, et al. The crystal structure of the secreted aspartic proteinase 3 from Candida albicans and its complex with pepstatin A. Proteins, (2007); 68(3): 738-748.

Calugi C, Guarna A, Trabocchi A. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, (2013); 28(5): 936-943.

Santos ALS, Braga-Silva LA, Goncalves DS, Ramos LS, Oliveira SSC, et al. Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from Candida albicans-In Silico, In Vitro and In Vivo Approaches. Journal of Fungi (Basel), (2021); 7(6): 424.

Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. Nature, (2023); 616(7958): 673-685.

Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharmaceutica Sinica B, (2022); 12(7): 3049-3062.

Schaduangrat N, Lampa S, Simeon S, Gleeson MP, Spjuth O, Nantasenamat C. Towards reproducible computational drug discovery. Journal of Cheminformatics, (2020); 12(1): 9.

Kontoyianni M. Docking and Virtual Screening in Drug Discovery. Methods in Molecular Biology, (2017); 1647: 255-266.

Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods in Molecular Biology, (2015); 1263: 243-250.

Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nature Reviews Disease Primers, (2018); 4: 18026.

Sardi JCO, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJS. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. Journal of Medical Microbiology, (2013); 62(Pt 1): 10-24.

Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiology and Molecular Biology Reviews, (2003); 67(3): 400-428.

Sayed Murad HA, M MR, Alqahtani SM, B SR, Alghamdi S, et al. Molecular docking analysis of AGTR1 antagonists. Bioinformation, (2023); 19(3): 284-289.

Kamal MA, H MB, I JH, R SA, M SH, et al. Insights from the molecular docking analysis of EGFR antagonists. Bioinformation, (2023); 19(3): 260-265.

Elaimi A, Hanadi MB, Almutairi A, Alniwaider RA, Abulkaliq MA, et al. Insights from the molecular docking analysis of GRP78 with natural compound inhibitors in the management of cancers. Bioinformation, (2023); 19(1): 39-42.

I JH, Alsharif FH, Aljadani M, Fahad Alabbas I, Faqihi MS, et al. Molecular docking analysis of KRAS inhibitors for cancer management. Bioinformation, (2023); 19(4): 411-416.

Chen D, Oezguen N, Urvil P, Ferguson C, Dann SM, Savidge TC. Regulation of protein-ligand binding affinity by hydrogen bond pairing. Science Advances, (2016); 2(3): e1501240.

Perfect JR. The antifungal pipeline: a reality check. Nature Reviews Drug Discovery, (2017); 16(9): 603-616.

Ortholand JY, Ganesan A. Natural products and combinatorial chemistry: back to the future. Current Opinion in Chemical Biology, (2004); 8(3): 271-280.

Ganesan A. The impact of natural products upon modern drug discovery. Current Opinion in Chemical Biology, (2008); 12(3): 306-317.

Newman DJ, Cragg GM. Natural Products as Sources of New Drugs from 1981 to 2014. Journal of Natural Products, (2016); 79(3): 629-661.




DOI: http://dx.doi.org/10.62940/als.v11i3.3218

Refbacks

  • There are currently no refbacks.